Brain-computer interface (BCI) technology, an avant-garde interdisciplinary domain bridging the brain with external devices, is rapidly evolving. It primarily divides into two categories: invasive and non-invasive. This technology exhibits vast potential for application across diverse sectors, including healthcare, education, consumer products, and intelligent driving, with notable preliminary achievements already witnessed in the medical realm. Non-invasive BCI products distinguish themselves with their wearability and high safety standards, whereas invasive products excel in precise control and clinical medical applications, despite encountering technical hurdles like biocompatibility and long-term stability.

The participating companies concurred that aligning regulatory policies with technological advancements and fostering integrated innovation in algorithms, chips, and materials are pivotal for realizing the industrialization of BCI technology. Furthermore, the commercialization process must navigate challenges such as low user acceptance and inadequate privacy protection, necessitating the reinforcement of ethical safety systems and market education.

Relevant stakeholders pledged to enhance the harmony between capital market reform and industrial policies, thereby infusing momentum into the growth of technology enterprises and the bolstering of new productivity.